Cited 7 times in
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박종숙 | - |
dc.contributor.author | 안철우 | - |
dc.date.accessioned | 2018-05-10T06:43:30Z | - |
dc.date.available | 2018-05-10T06:43:30Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1368-5031 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/158514 | - |
dc.description.abstract | AIMS: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). METHODS: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index <40 kg/m(2) . A total of 207 subjects were randomised into the GM-SR group (n=101) or the GM group (n=106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. RESULTS: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p=0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p=0.01 in the intention to treat set). CONCLUSIONS: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Blood Glucose/metabolism | - |
dc.subject.MESH | Delayed-Action Preparations | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/blood | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glycated Hemoglobin A/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/administration & dosage* | - |
dc.subject.MESH | Hypoglycemic Agents/adverse effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Medication Adherence | - |
dc.subject.MESH | Metformin/administration & dosage* | - |
dc.subject.MESH | Metformin/adverse effects | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Sulfonylurea Compounds/administration & dosage* | - |
dc.subject.MESH | Sulfonylurea Compounds/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Y.-C. Hwang | - |
dc.contributor.googleauthor | M. Kang | - |
dc.contributor.googleauthor | C. W. Ahn | - |
dc.contributor.googleauthor | J. S. Park | - |
dc.contributor.googleauthor | S. H. Baik | - |
dc.contributor.googleauthor | D. J. Chung | - |
dc.contributor.googleauthor | H. C. Jang | - |
dc.contributor.googleauthor | K.-A. Kim | - |
dc.contributor.googleauthor | I.-K. Lee | - |
dc.contributor.googleauthor | K. W. Min | - |
dc.contributor.googleauthor | M. Nam | - |
dc.contributor.googleauthor | T. S. Park | - |
dc.contributor.googleauthor | S. M. Son | - |
dc.contributor.googleauthor | Y.-A. Sung | - |
dc.contributor.googleauthor | J.-T. Woo | - |
dc.contributor.googleauthor | K. S. Park | - |
dc.contributor.googleauthor | M.-K. Lee | - |
dc.identifier.doi | 10.1111/ijcp.12071 | - |
dc.contributor.localId | A01660 | - |
dc.contributor.localId | A02270 | - |
dc.relation.journalcode | J01099 | - |
dc.identifier.eissn | 1742-1241 | - |
dc.identifier.pmid | 23336668 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12071/abstract | - |
dc.contributor.alternativeName | Park, Jong Suk | - |
dc.contributor.alternativeName | Ahn, Chul Woo | - |
dc.contributor.affiliatedAuthor | Park, Jong Suk | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Woo | - |
dc.citation.volume | 67 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 236 | - |
dc.citation.endPage | 243 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Vol.67(3) : 236-243, 2013 | - |
dc.identifier.rimsid | 43116 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.